Defining the risks for cytomegalovirus infection and disease after solid organ transplantation.
about
Dynamic expression of Qa-2 during acute graft rejectionThe role of belataceptin transplantation: results and implications of clinical trials in the context of other new biological immunosuppressant agents.Cytomegalovirus infection in liver transplant recipients: updates on clinical managementThe effect of different immunoprophylaxis regimens on post-transplant cytomegalovirus (CMV) infection in CMV-seropositive liver transplant recipients.Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis.KIR-associated protection from CMV replication requires pre-existing immunity: a prospective study in solid organ transplant recipients.
P2860
Defining the risks for cytomegalovirus infection and disease after solid organ transplantation.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Defining the risks for cytomeg ...... r solid organ transplantation.
@en
Defining the risks for cytomeg ...... r solid organ transplantation.
@nl
type
label
Defining the risks for cytomeg ...... r solid organ transplantation.
@en
Defining the risks for cytomeg ...... r solid organ transplantation.
@nl
prefLabel
Defining the risks for cytomeg ...... r solid organ transplantation.
@en
Defining the risks for cytomeg ...... r solid organ transplantation.
@nl
P2093
P2860
P356
P1433
P1476
Defining the risks for cytomeg ...... r solid organ transplantation.
@en
P2093
Carolynn Pietrangeli
G Mark Baillie
Robert J Stratta
P2860
P304
P356
10.1592/PHCO.30.2.144
P407
P577
2010-02-01T00:00:00Z